Views

CrossRef citations to date

Altmetric

Letters to Editor

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

Alba Cabirtaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainCorrespondence[email protected]

https://orcid.org/0000-0001-7198-8894

Gloria Hidalgo-Gómeza Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

https://orcid.org/0000-0003-3599-1724

Ana Marín-Nieblaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

https://orcid.org/0000-0002-7592-6815

Laura Gallura Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

Silvia Saumella Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

https://orcid.org/0000-0001-8635-4376

Josep Castellvíc Department of Pathology, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain

https://orcid.org/0000-0001-5745-9996

Eva Cataláa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

https://orcid.org/0000-0003-3478-9110

Adoración Blancoa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Laura López-Andreonia Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

María Julia Montoroa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

https://orcid.org/0000-0001-9532-7417

Mayda Navarretea Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

Carlos Palacio-Garcíaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

https://orcid.org/0000-0002-9085-3327

Bárbara Tazón-Vegaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Sabela Bobilloa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

Francesc Boscha Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

Margarita Ortegaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

https://orcid.org/0000-0002-1985-3965

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

The following represents disclosure information provided by the authors of this manuscript. BTV has received honoraria from Janssen, Novartis and Bristol Myers Squibb. AMN has received honoraria from Lilly, Kite, AstraZeneca, AbbVie, BeiGene, Janssen, Takeda, and Kiowa Kirin. SB has received honoraria from Gilead and Roche. FB has received honoraria from Janssen, Karyospharm, Mundipharma, BeiGene, Gilead, Roche, AbbVie, Celgene/BMS, AstraZeneca, Novartis, Lilly and Takeda. All remaining authors have no conflicts to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

Information for

Open access

Opportunities

Help and information

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature